231 related articles for article (PubMed ID: 2466548)
1. Chemotherapy of invasive thymoma. A retrospective study of 22 cases.
Göldel N; Böning L; Fredrik A; Hölzel D; Hartenstein R; Wilmanns W
Cancer; 1989 Apr; 63(8):1493-500. PubMed ID: 2466548
[TBL] [Abstract][Full Text] [Related]
2. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
3. Thymoma. A retrospective study of 87 cases.
Park HS; Shin DM; Lee JS; Komaki R; Pollack A; Putnam JB; Cox JD; Hong WK
Cancer; 1994 May; 73(10):2491-8. PubMed ID: 8174044
[TBL] [Abstract][Full Text] [Related]
4. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
5. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
6. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
[TBL] [Abstract][Full Text] [Related]
7. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
8. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
9. [Invasive thymoma with pulmonary metastasis. Complete remission 5 years after surgery and chemotherapy using the CHOP-BLEO protocol].
Wurtz A; Ramon P; Chambon JP; Wallaert B; Gosselin B
Rev Mal Respir; 1988; 5(6):651-4. PubMed ID: 2464185
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for invasive thymoma. A 13-year experience.
Fornasiero A; Daniele O; Ghiotto C; Piazza M; Fiore-Donati L; Calabró F; Rea F; Fiorentino MV
Cancer; 1991 Jul; 68(1):30-3. PubMed ID: 2049749
[TBL] [Abstract][Full Text] [Related]
11. Failure of conventional chemotherapy in aggressive lymphomas.
Cunningham D; Hepplestone A; Gilchrist NL; Dagg JH; Evans IL; Soukop M
Postgrad Med J; 1987 Jan; 63(735):11-5. PubMed ID: 2444960
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of invasive thymoma.
Fornasiero A; Daniele O; Ghiotto C; Sartori F; Rea F; Piazza M; Fiore-Donati L; Morandi P; Aversa SM; Paccagnella A
J Clin Oncol; 1990 Aug; 8(8):1419-23. PubMed ID: 2380761
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of malignant thymoma. Case report and review of the literature.
Hu E; Levine J
Cancer; 1986 Mar; 57(6):1101-4. PubMed ID: 3080220
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
Kim ES; Putnam JB; Komaki R; Walsh GL; Ro JY; Shin HJ; Truong M; Moon H; Swisher SG; Fossella FV; Khuri FR; Hong WK; Shin DM
Lung Cancer; 2004 Jun; 44(3):369-79. PubMed ID: 15140551
[TBL] [Abstract][Full Text] [Related]
16. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease.
Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U
Leuk Lymphoma; 1994 Jun; 14(1-2):79-89. PubMed ID: 7522721
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
[TBL] [Abstract][Full Text] [Related]
19. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.
Loehrer PJ; Kim K; Aisner SC; Livingston R; Einhorn LH; Johnson D; Blum R
J Clin Oncol; 1994 Jun; 12(6):1164-8. PubMed ID: 8201378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
